Endoscopic pancreatic function test using combined secretin and cholecystokinin stimulation for the evaluation of chronic pancreatitis - 21/03/12
Reprint requests: Tyler Stevens, MD, Digestive Disease Institute, The Cleveland Clinic, 9500 Euclid Avenue, Desk A31, Cleveland, OH 44195Résumé |
Background |
Current endoscopic pancreatic function test (ePFT) methods use either secretin or cholecystokinin (CCK) to measure pancreatic function.
Objective |
To evaluate a novel ePFT protocol that includes both secretin and CCK stimulation and to assess which fluid parameters best discriminate patients with chronic pancreatitis (CP).
Design |
Prospective, cross-sectional diagnostic study.
Setting |
Single, tertiary-care institution.
Patients |
Healthy volunteers and patients evaluated for CP were included.
Interventions |
All patients underwent a combined secretin-CCK ePFT. Patients evaluated for CP also underwent EUS during the same endoscopic session.
Main Outcome Measurements |
Duodenal fluid bicarbonate, lipase, and amylase concentrations were measured after CCK and secretin stimulation. Results were compared based on the presence of CP detected by EUS (≥5 features).
Results |
Twenty healthy volunteers and 69 patients evaluated for CP completed the secretin and CCK ePFT. Patients with an EUS score of 5 or higher had significantly decreased peak bicarbonate concentrations (72 mmol) compared with patients with an EUS score lower than 5 (90 mmol) and healthy subjects (108 mmol) (P < .001). Peak concentrations of amylase and lipase and total fluid volume were not significantly different between patients with CP and controls. Receiver-operating characteristic analysis revealed that peak bicarbonate concentration had superior discrimination for CP (area under the curve [AUC] 0.738) compared with peak amylase (AUC 0.677) and peak lipase (AUC 0.627). The addition of enzyme concentration measurement did not improve discrimination compared with peak bicarbonate alone.
Limitations |
Secretin and cholecystokinin endoscopic pancreatic function test (SC ePFT) results were not compared with those of single hormone ePFTs.
Conclusions |
The addition of CCK infusion and enzyme concentration measurement to a standard secretin ePFT does not enhance the diagnosis of CP.
Le texte complet de cet article est disponible en PDF.Abbreviations : AUC, CCK, CP, ePFT, PFT, SC ePFT
Plan
| DISCLOSURE: The following author disclosed a financial relationship relevant to this publication: Dr. Stevens: research grant from Abbott Pharmaceuticals. The other authors disclosed no financial relationships relevant to publication. Funding for this investigator-initiated study was provided by Abbott. Portions of this study were performed in The Cleveland Clinic Clinical Research Unit, supported in part by the National Institutes of Health, National Center for Research Resources, CTSA 1UL1RR024989, Cleveland, Ohio. |
Vol 75 - N° 4
P. 764-768 - avril 2012 Retour au numéro
Article précédent
- Management of malignant gastric outlet obstruction with a modified triple-layer covered metal stent
- Hiroyuki Isayama, Takashi Sasaki, Yousuke Nakai, Osamu Togawa, Hirofumi Kogure, Naoki Sasahira, Yoko Yashima, Kazumichi Kawakubo, Yukiko Ito, Kenji Hirano, Takeshi Tsujino, Nobuo Toda, Minoru Tada, Masao Omata, Kazuhiko Koike
- Clinical impact of K-ras mutation analysis in EUS-guided FNA specimens from pancreatic masses
- Takeshi Ogura, Kenji Yamao, Akira Sawaki, Nobumasa Mizuno, Kazuo Hara, Susumu Hijioka, Yasumasa Niwa, Masahiro Tajika, Shinya Kondo, Yasuhiro Shimizu, Vikram Bhatia, Kazuhide Higuchi, Waki Hosoda, Yasushi Yatabe
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?